Jenburkt Pharmaceuticals Ltd — Updates, 20-05-2025: Company Update

Jenburkt Pharmaceuticals has announced a board meeting approving the financial results for the quarter and financial year ended March 31, 2025. The company declared a 180% dividend per share on 44.13 lakh equity shares for FY25. The 40th Annual General Meeting will be held via video conferencing. Shri Ashish Uttam Bhuta was appointed as a director on rotation and re-appointed as Chairman and Managing Director for five years from April 1, 2026, with remuneration terms approved for three years. The auditors issued an unmodified opinion on the standalone financials.

Revenue grew to Rs 151.69 Cr in FY25 from Rs 141.97 Cr, with profit before tax at Rs 43.93 Cr (up from Rs 35.18 Cr). Profit after tax rose to Rs 32.06 Cr versus Rs 25.98 Cr last year. Earnings per share were Rs 72.65 compared to Rs 58.86. Net cash from operations increased substantially to Rs 27.91 Cr. Capital work-in-progress and investments rose significantly, supporting expansion. The company maintains strong internal controls and compliance, with no material concerns or defaults reported.